Patients with chronic HCV infection
Conditions
Interventions
None listed
Sponsors
Hokkaido University Department of Gastroenterology and Hepatology, Graduate School of Medicine,
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients (1) with the target disease who (2) satisfy all the inclusion criteria and (3) meet none of the exclusion criteria are eligible for the study. (1) Subjects Patients treated with anti-HCV therapy between January 2001 and December 2018 and having proper preserved serum for research (2) Inclusion criteria [1] Patients who are 20 years of age or older at the time of treatment [2] Patients who have been treated with anti-HCV therapy [3] Patients with an informed consent or patients without rejection to entry this study
Exclusion criteria
Exclusion criteria: 1) Patients with poorly controlled cardiac disease (e.g., myocardial infarction, cardiac failure, arrhythmia) 2) Patients with severe hepatic impairment 3) Patients deemed unsuitable for study entry by their treating physician or principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the frequency of the HBV reactivation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To analyze the predictors for HBV reactivation during and after anti-HCV therapy. 2.To analyze the change in HBs antibody titer during and after anti-HCV therapy and to analyze the predictors related to HBs antibody decline. 3.To conduct stratified analysis based on treatment with or without IFN | — |
Countries
Japan
Contacts
Public ContactGOki Suda
Hokkaido University Department of Gastroenterology and Hepatology, Graduate School of Medicine,
Outcome results
None listed